Ceramedix Joins Johnson & Johnson Innovation

NEW YORK, May 30, 2023 /PRNewswire/ — Ceramedix, Inc., a privately-held biotherapeutics company developing a new class of antibody-based drugs designed with the aim to address novel disease targets involving the microvasculature, today announced it has joined Johnson & Johnson Innovation –  JLABS (JLABS) as a resident company.  Charles L. Dimmler, III, Executive Chairman of Ceramedix, … Read more